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EPIDEMIOLOGY AND PREVENTION
Trends in HIV Prevalence in Pregnant Women
in Rural South Africa
Ayesha B. M. Kharsany, PhD,* Janet A. Frohlich, DCur,* Nonhlanhla Yende-Zuma, MS,*
Gethwana Mahlase, BCur,† Natasha Samsunder, BTech,* Rachael C. Dellar, MS,*
May Zuma-Mkhonza, BCur,‡ Salim S. Abdool Karim, MBChB, PhD,*§ and
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Background: Despite substantial progress in the delivery of HIV
prevention programs, some communities continue to experience high
rates of HIV infection. We report on temporal trends in HIV
prevalence in pregnant women in a community in rural KwaZulu-
Natal in South Africa.
Methods: Annual, anonymous cross-sectional HIV sero-prevalence
surveys were conducted between 2001 and 2013 among first visit
prenatal clinic attendees. The time periods 2001 to 2003 were
defined as pre-antiretroviral therapy (ART), 2004 to 2008 as early
ART, and 2009 to 2013 as contemporary ART roll-out, to
correspond with the substantial scale-up of ART program.
Results: Overall, HIV prevalence rose from 35.3% [95% confi-
dence interval (CI): 32.3 to 38.3] pre-ART (2001–2003) to 39.0%
(95% CI: 36.8 to 41.1) in the early ART (2004–2008) to 39.3% (95%
CI: 37.2 to 41.4) in the contemporary ART (2009–2013) roll-out
periods. In teenage women (,20 years), HIV prevalence declined
from 22.5% (95% CI: 17.5 to 27.5) to 20.7% (95% CI: 17.5 to 23.8)
and to 17.2% (95% CI: 14.3 to 20.2) over the similar ART roll-out
periods (P = 0.046). Prevalence increased significantly in women 30
years and older (P , 0.001) over the same time period largely
because of survival after ART scale up. Teenage girls with male
partners of age 20–24 and $ 25 years had a 1.7-fold (95% CI:
1.3–2.4; P = 0.001) and 3-fold (95% CI: 2.1 to 4.3; P , 0.001)
higher HIV prevalence respectively.
Conclusions: Notwithstanding the encouraging decline in teen-
agers, the ongoing high HIV prevalence in pregnant women in this
rural community, despite prevention and treatment programs, is
deeply concerning. Targeted interventions for teenagers, especially
for those in age-disparate relationships, are needed to impact this
HIV epidemic trajectory.
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INTRODUCTION
In 2012, the Joint United Nations Program on HIV/
AIDS estimated that approximately 6.1 million (95% CI: 5.8
to 6.4 million) people in South Africa were living with HIV,
having the highest burden of infection in the world despite
being home to ,1% of the global population.1 The epidemic
in South Africa, that also has the highest number of AIDS
cases globally, has been described as “hyper-endemic,
generalized and mature.”2 Preventing further infections in
such settings requires an in-depth understanding of the
epidemic and to design customized locally responsive
interventions accordingly.3–5
Since 2002, the 2-dose nevirapine regimen to prevent
mother to child transmission of HIV has been available to all
pregnant HIV sero-positive women who choose to have an
HIV test and accept the prevention of mother to child
transmission intervention. Parallel to these services, through
the district hospitals, the South African Ministry of Health,
initiated antiretroviral therapy (ART) provision to HIV-
positive adults, meeting the ART eligibility criteria of CD4
cell count of ,200/mL. By March 2005, at least one service
point for AIDS-related care and treatment was established in
each of the country’s 53 districts. By 2008 about 588,000
people had initiated ART6; and contemporary ART roll-out
continued to improve, with almost 2 million adults and
children receiving ART in 2011, representing just over 50%
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of those eligible for treatment under World Health Organiza-
tion guidelines of CD4 cell count of ,350/mL.7,8
In 2004, the Centre for the AIDS Programme of
Research in South Africa (CAPRISA) through its research
facilities in rural Vulindlela, uMgungundlovu district,
KwaZulu-Natal (KZN) initiated the free provision of ART
to patients with AIDS, who met the eligibility criteria defined
by the Department of Health.9 Over time, the decentralization
of services and nurse-initiated management of ART through
primary health care clinics facilitated the roll-out, scale up,
and the retention of patients in ART programs. In parallel, the
burden of managing uncomplicated cases at referral hospitals
also reduced. To enhance the rapid scale-up of ART, mobile
teams help to initiate patients at hard to reach areas such as
farms, and for those having difficulty leaving their work
premises to attend clinics. Community care givers play an
important role and actively assist with tracing patients who
default treatment, and have been successful in reintroducing
them back to the health facilities. Through this comprehen-
sive and incremental approach, the highest HIV burden
district of uMgungundlovu made remarkable progress on
ART provision and the number of patients on ART increased
from 61,230 in 201110 to 111,691 by 2014.11
To monitor temporal trends in the evolving epidemic,
the South African government has undertaken annual,
anonymous, HIV prevalence surveys among pregnant
women utilizing public sector prenatal clinics.12 These and
other data13 have highlighted the differences within and
between South African provinces, with the province of KZN
having the highest prevalence of HIV.14 As epidemics
mature with increasing coverage of ART, prevalence of
HIV infection is a less reliable marker of the evolving
epidemic, since survival improves, and prevalence is
expected to increase and mask new infections. However,
measuring HIV prevalence in young, pregnant women ,24
years, provides a reliable indirect measurement of new
infections, as they are more likely to have recently become
sexually active, and therefore infection is more likely to be
recent. Since 2001, we have conducted complementary
annual HIV prevalence surveys in prenatal clinics in rural
KZN in one of the 3 highest burden HIV health districts12
where extensive HIV prevention and treatment programs are
being implemented. The purpose of this study was to assess
the trends in HIV prevalence in pregnant women after the
introduction and scale-up of ART, and selected risk factors
associated with HIV transmission in this setting.
METHODS
Study Setting
Surveys were undertaken in Vulindlela, a rural com-
munity located about 150 km west of Durban in the province
of KZN, home to approximately 150,000 residents and
characterized by high levels of poverty and unemployment.
Health care in Vulindlela is accessed from 7 nurse-run
primary health care clinics that deliver an essential package
of health services that includes prenatal care, family
planning, childhood immunization, minor ailment services,
and management of common chronic conditions at no cost.
HIV testing services are available at these clinics with pre-
and post-test counseling.
Study Procedures
The South African Department of Health’s National
Antenatal Sentinel HIV and Syphilis Prevalence Surveys are
conducted annually among pregnant women, and blood
samples are tested using a single enzyme-linked immunosor-
bent assay (ELISA) (Abbott Axsym System for HIV-1/HIV-2;
Abbott Laboratories, Chicago, IL).
Coinciding with these surveys, we conducted cross
sectional surveys from October 1st to November 30th of
each year from 2001 to 2013. Consecutive pregnant women
who presented for their first prenatal care visit at one of the
7 primary health care clinics, regardless of age were eligible
to participate.
All women were provided with study information on
anonymized HIV testing for surveillance. As part of routine
prenatal care, blood samples are collected for hemoglobin
and syphilis testing, and women were requested to provide
an additional sample for HIV testing. During each survey,
after verbal informed consent, trained nurses administered
a questionnaire to obtain minimal key demographic and
behavioral data. This included the age of the woman, her
current partner’s age, if this was her first pregnancy, and
dates of prior pregnancies, knowledge of HIV status, and
exposure to antiretroviral therapy (ART).The details were
recorded on a standardized case report form labelled with
a unique participant identification number. Peripheral blood
was collected in prelabelled EDTA and plain tubes.
Samples were transported to the central laboratory in
Durban for HIV testing after removal of all identifiers.
With the aid of a unique participant identification number,
HIV test results were linked to demographic and behavioral
data; from 2004 to current partner’s age and prior
pregnancies, and from 2009 to exposure to ART. The
survey protocol was in compliance with the World Health
Organization’s and South African Department of Health’s
guidelines for the conduct of anonymized HIV sur-
veys,12,15–17 and was reviewed and approved by the
University of KwaZulu-Natal Biomedical Research Ethics
Committee (Reference number E179/04).
Laboratory Testing Procedures
In 2001 and 2002, HIV testing was performed using
ELISA (Abbott AxSYM system for HIV-1/HIV-2; Abbott
Laboratories). In 2003, specimens were tested using a rapid
assay (Abbott Determine, Abbott Park, IL) with all positives
confirmed using a second rapid assay (Capillus, Trinity
Biotech, Bray, Wicklow, Ireland). From 2004 to 2013,
specimens were tested by ELISA (Enzygnost, Dade Behring,
Mannheim, Germany). Any specimen indicating an indeter-
minate result was further tested with the Abbott Determine
rapid assay. All these tests perform similarly with sensitivities
and specificities in excess of 98%.18
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Data Analysis
Data were analyzed using SAS version 9.3 (SAS
Institute, Cary, NC). All statistical tests are 2 sided and CIs
are at 95% level. Based on consistency in the age structure of
the cohort over time, pooled summary data for women are
reported for the time periods 2001 to 2003 (as pre-ART roll-
out), 2004 to 2008 (early ART roll-out), and 2009 to 2013
(contemporary ART roll-out) to correspond with the delivery
of the ART program in KZN.7
The overall HIV prevalence and 95% CI were calcu-
lated and reported for age stratified groups. The Cochran-
Armitage x2 test was used to test for linear trend in HIV
prevalence over time. Log-binomial regression adjusted for
previous pregnancy and clinic was used to determine whether
the age of current male sexual partner was associated with
HIV infection in women. We included the clinic in the model
to adjust for clustering because the clinics were of different
sizes and HIV prevalence varied across clinics. We assumed
that women who had been pregnant before were at high risk
of HIV, and that previous pregnancy could confound age and
HIV status. This analysis was stratified by the women’s age
groups ,20, 20–24 and $25 years.
RESULTS
Demographic Characteristics
Between 2001 and 2013, a total of 5075 pregnant
women attending prenatal clinics in the rural Vulindlela sub
district of KZN were included in annual HIV prevalence
surveys, with a mean of 390 (range 225–552) women
surveyed per year.
The age distribution of surveyed women attending
prenatal clinics showed that the proportion of women in
the ,20 year age group was 33.7% in the 2001–2003
period, 32.9% in the 2004–2008 period, and 30.6% in the
2009–2013 period and was the highest compared to other
age groups. The proportion of women aged 20–24 years
increased from 28.1% in the 2001–2003 period to 30.3% in
the period 2004–2008 and was 29.3% in the 2009–2013
period. However, the proportion of women in the age groups
25–29, 30–34, and $35 years was consistently lower across
all time periods (see Table S1, Supplemental Digital
Content, http://links.lww.com/QAI/A718).
Temporal Trends in HIV Prevalence
Table 1 shows the overall and age specific HIV
prevalence. The overall HIV prevalence increased from
35.3% (95% CI: 32.3 to 38.3) in the period 2001–2003 to
39.0% (95% CI: 36.8 to 41.1) in the period 2004–2008 and
to 39.3% (95% CI: 37.2 to 41.4) in the 2009–2013 period;
(P = 0.058). Age-stratified analysis showed that HIV
prevalence in teenagers ,20 years was 22.5% (95% CI:
17.5 to 27.5) in the 2001–2003 period and decreased to
20.7% (95% CI: 17.5 to 23.8) in the period 2004–2008 and
to 17.2% (95% CI: 14.3 to 20.2) in the 2009–2013 period;
(P = 0.046). Similarly, in women in the 20–24 year age
group, the prevalence was 45.5% (95% CI: 38.9 to 52.0) in
the period 2001–2003 and declined to 44.2% (95% CI: 40.2
to 48.2) in the period 2004–2008 and to 37.9% (95%
CI: 34.0 to 41.8) in the period 2009–2013; (P = 0.018). In
women aged 25–29 years, HIV prevalence remained
relatively constant and was 47.9% (95% CI: 40.3 to
55.5), 58.8% (95% CI: 53.5 to 64.2), and 57.6% (95%
CI: 52.7 to 62.4); (P = 0.085) over the same time period.
Among women 30–34 years, HIV prevalence increased
from 26.7% (95% CI: 16.7 to 36.7) to 55.5% (95% CI: 49.0
to 62.0) and to 59.9% (95% CI: 53.9 to 66.0); (P , 0.001),
and in women 35 years and older HIV prevalence increased
from 27.4% (95% CI: 16.3 to 38.5) to 30.8% (95% CI: 23.8
to 37.7) and to 53.4% (95% CI: 46.0 to 60.8); (P , 0.001)
over the same time periods. Figure 1 shows the decline in
HIV prevalence in the ,20 and 20–24 year age group, with
prevalence increasing in the 25–29, 30–34 and $35 year
age groups.
The trends in HIV prevalence in young women are
presented in 2-year age groups in Table 2. Given that HIV
infection in women ,24 years could be regarded as a reliable
measure of incident infections,19 thus has substantial bearing
on assessing epidemic control progress in terms of reducing
new infections.19 In all survey periods, a substantial increase
in HIV prevalence was observed as women transitioned from
their late teens to early twenties (Table 2). Substantial
reductions in HIV prevalence from 22.2% (95% CI: 12.6 to
31.8) to 10.6% (95% CI: 6.0 to 15.2) and to 7.7% (95% CI:
3.7 to 11.8); (P = 0.003) were observed in the #16 year olds,
but rapid increase in HIV prevalence from age 17 years and
over were common to all study periods, with little variation
over time. In this setting, by age 24 years, 54.4% (95% CI:
43.4 to 65.4), 51.1% (95% CI: 43.9 to 58.2) and 46.3% (95%
CI: 39.6 to 52.9); (P = 0.176) of young pregnant women were
HIV-positive in the periods 2001–2003, 2004–2008 and
2009–2013, respectively.
Temporal Trends in Sexual Partner Age
Disparity and HIV Prevalence
Data on age disparity, in the sexual relationships
engaged by surveyed pregnant women were collected from
2003, and was available for 4160 women (82.0%). Overall,
between 2003 and 2013, HIV prevalence was higher in
women who reported currently having older sexual partners
compared with those having partners either the same age or
younger than themselves. Table 3 shows the association
between current sexual partner’s age and HIV infection
stratified by woman’s age. Among teenagers ,20 years, the
adjusted relative risk (ARR) for HIV infection with current
sexual partner in the age group 20–24 years was 1.7 (95%
CI: 1.3 to 2.4); (P = 0.001) and increased to 3.0 (95% CI: 2.1
to 4.3); (P , 0.001) if the current sexual partner was $25
years. For young women aged 20–24 years whose current
sexual partner was ,20 years, the ARR was 0.3 (95% CI:
0.1 to 1.2); (P = 0.097), but increased significantly to 1.3
(95% CI: 1.2 to 1.6); (P , 0.001) with a partner $25 years.
In contrast, for women $25 years, the age of the current
sexual partner was not associated with HIV infection;
ARR = 1.0 (95% CI: 0.7 to 1.5); (P = 0.869).
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DISCUSSION
Our surveys highlight the consistently high burden of
HIV infection borne by young pregnant women in this rural
community, which may be explained at least in part by young
women engaging in high-risk sexual intercourse. HIV
prevalence has remained unprecedentedly high: in excess of
40% in women aged 20–24 years, and in excess of 50% in
women aged 25–34 years. The overall high prevalence in this
age group is deeply concerning despite the prevention and
treatment programs, and additional targeted interventions—
especially for those in age-disparate relationships— are
needed to impact this HIV epidemic.
Although the roll-out of ART in 2004 in this community
appears to have had a substantial impact on survival, age-
specific HIV prevalence provides a clear explanation for lack
of progress in reducing the disease burden despite the presence
of numerous prevention interventions. Although there has been
a significant decline in HIV prevalence in the #16 year age
group, indeed, we report exceptionally high and relatively
unchanged HIV prevalence in young women (17.2% in women
,20 years in the 2009–2013 study period), which suggests that
reductions in new infections in this population have
been minimal, given that in generalized epidemic settings such
as South Africa, HIV prevalence in 15–24-year -olds is
considered a reliable measurement to approximate trends in
incident infections.19,20 Assuming that HIV transmission is
highest during early and acute HIV infection, the burden of
potential incident infections in these teenagers and young
women is deeply concerning, and has serious implications for
fueling the HIV epidemic in this community,21–24 though the
slight declines in HIV prevalence in the teenage groups are
promising against the existing sheer high burden of infection.
Moreover, significantly altering epidemic trajectories in similar
settings will require prevention interventions targeted at teen-
agers and young women, and understanding the risk factors
associated with HIV acquisition in this key population.
The association reported here between high HIV prev-
alence and increased age of sexual partners for women #24
years, which increases in strength in women ,20 years of age
is consistent with other reports.13,25–29 There is an urgent need
to understand the causality of this association and how it is
evolving with time, and the reasons why teenagers and young
women in this community engage sexually with older men. To
what extent partnerships leading to sexual intercourse are
impacted by the need for financial support in young women,
illness and death in women over 25 years, and other complex
cultural factors is undetermined.26
Furthermore, monitoring the impact of ART provision
and the survival of women over 25 years continues to be
critical; the high burden of HIV observed in this age group
reflects the cumulative effect of HIV acquisition, underscores
the extent of the care burden, and may help inform future
prevention and treatment efforts. Although HIV prevalence in
South Africa varies widely by province and the generaliz-
ability of results is limited, our surveys starkly demonstrate
the unprecedented scale of the HIV epidemic at a local level.
The surveys also provide some bearing on the implications of
the epidemic for the community. For example, the low
proportion of pregnancies in the pre-ART roll-out period
(2001–2003) in women over 30 years reported here, may be
attributable to declines in fertility rate as a result of advancing
HIV disease, and high mortality rates in this group.30–34
TABLE 1. Temporal Trends in HIV Prevalence by Age in Pregnant Women Attending Prenatal Clinics in Vulindlela, Rural KwaZulu-
Natal by Survey Periods 2001–2003, 2004–2008, and 2009–2013
Age Group
2001–2003 2004–2008 2009–2013
P*n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
,20 60/267 22.5 (17.5 to 27.5) 133/644 20.7 (17.5 to 23.8) 109/633 17.2 (14.3 to 20.2) 0.046
20–24 101/222 45.5 (38.9 to 52.0) 262/593 44.2 (40.2 to 48.2) 230/607 37.9 (34.0 to 41.8) 0.018
25–29 79/165 47.9 (40.3 to 55.5) 190/323 58.8 (53.5 to 64.2) 232/403 57.6 (52.7 to 62.4) 0.085
30–34 20/75 26.7 (16.7 to 36.7) 126/227 55.5 (49.0 to 62.0) 151/252 59.9 (53.9 to 66.0) ,0.001
$35 17/62 27.4 (16.3 to 38.5) 52/169 30.8 (23.8 to 37.7) 94/176 53.4 (46.0 to 60.8) ,0.001
Total† 345/977 35.3 (32.3 to 38.3) 778/1996 39.0 (36.8 to 41.1) 826/2102 39.3 (37.2 to 41.4) 0.058
*Cochran-Armitage x2 test for linear trend.
†Includes women with missing age.
FIGURE 1. Trends in HIV prevalence in pregnant women by
survey period; 2001–2003, 2004–2008, and 2009–2013.
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In this setting, HIV acquisition is almost synonymous
with sexual debut, which is estimated at around age 16
years.27,35 Further, the burden of teenage pregnancies in the
community, which represent an average of 30% of the
surveyed pregnancies sampled per year from 2001 to 2013,
is concerning, given associations with poor economic
and educational outcomes.27,36 Although several, largely
government-initiated and school-based behavioral interven-
tions and educational outreach programs have aimed to target
the teenage female population, these data demonstrate their
limited success in terms of reducing pregnancy and HIV
infection rates in teenagers. Despite several behavioral
interventions currently implemented to reduce the sexual
transmission of HIV, including programs aimed at delaying
sexual debut, preventing intergenerational sex, medical male
circumcision, promoting condom use within the structured
ABC guidelines (abstinence, being faithful to one’s partner,
and condom use), and even with earlier access to ART, which
has been shown to prevent HIV transmission in randomized
clinical trials37 and observational cohorts,38 HIV incidence
and prevalence remains persistently high in teenage girls.39–41
It is clear that these teenage girls are a key group for HIV
prevention, and understanding of HIV transmission dynamics
in this population is a major gap in the knowledge of HIV
epidemiology. The severity of the epidemic in this setting
creates an imperative for the inclusion of teenagers ,18 years
in biomedical trials42 with both HIV incidence and other
sexual and reproductive health endpoints.
There are several limitations to our study. Our survey
population comprising pregnant women seeking prenatal care
limits generalizability beyond this group, as HIV prevalence
is likely to be very different among similar age, nonpregnant
women in this community.43 Furthermore, pregnant women
attending the clinic for the first time for a current pregnancy
are provided with comprehensive health care and we included
all women in the study; however, it is possible that some
women might have been missed and therefore the prevalence
could potentially be overestimated. The subgroup analysis on
the association between the current sexual partner’s age and
HIV infection stratified by woman’s age, although limited by
the small sample size across each year, demonstrated that this
effect is more distinct in teenagers ,20 years. However, as
women get older it is not clear whether boys and younger men
are at risk of infection from older women. More detailed
phylogenetic analysis of HIV-1 sequences and phylodynamic
studies are needed to better understand the precise bi-
directionality of infection to sexual partners across all age
groups. As surveillance spanned over several years, the
TABLE 2. Temporal Trends in HIV Prevalence in #24 Year Old Pregnant Women Attending Prenatal Clinics in Vulindlela, Rural
KwaZulu-Natal by Survey Periods 2001–2003, 2004–2008 and 2009–2013
Age Group
2001–2003 2004–2008 2009–2013
P*n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
#16 16/72 22.2 (12.6 to 31.8) 18/170 10.6 (6.0 to 15.2) 13/168 7.7 (3.7 to 11.8) 0.003
17–18 34/144 23.6 (16.7 to 30.5) 69/324 21.3 (16.8 to 25.8) 68/336 20.2 (15.9 to 24.5) 0.423
19–20 34/108 31.5 (22.7 to 40.2) 99/300 33.0 (27.7 to 38.3) 77/282 27.3 (22.1 to 32.5) 0.245
21–22 34/86 39.5 (29.2 to 49.9) 113/255 44.3 (38.2 to 50.4) 82/240 34.2 (28.2 to 40.2) 0.124
23–24 43/79 54.4 (43.4 to 65.4) 96/188 51.1 (43.9 to 58.2) 99/214 46.3 (39.6 to 52.9) 0.176
Total 161/489 32.9 (28.8 to 37.1) 395/1237 31.9 (29.3 to 34.5) 339/1240 27.3 (24.9 to 29.8) 0.007
*Cochran-Armitage x2 test for linear trend.
TABLE 3. Multiple Log Binomial Regression Examining the Association of Current Partner’s Age and HIV Infection Among
Pregnant Women attending Prenatal Clinics in Rural KwaZulu-Natal, 2003–2013. Unadjusted and Adjusted Relative Risk, 95% CI
for Prevalent HIV Infection
Age Group Partner’s Age Group
HIV Prevalence Unadjusted Adjusted*
% (95% CI) RR (95% CI) P ARR (95% CI) P
,20 ,20 10.8 (7.8 to 13.7) Reference —
20–24 20.4 (17.5 to 23.3) 1.9 (1.4 to 2.6) ,0.001 1.7 (1.3 to 2.4) 0.001
$25 32.9 (25.3 to 40.4) 3.1 (2.1 to 4.4) ,0.001 3.0 (2.1 to 4.3) ,0.001
20–24 ,20 10.0 (0.0 to 23.1) 0.3 (0.1 to 1.1) 0.062 0.3 (0.1 to 1.2) 0.097
20–24 35.1 (31.0 to 39.2) Reference —
$25 46.6 (42.9 to 50.3) 1.3 (1.2 to 1.5) ,0.001 1.3 (1.2 to 1.6) ,0.001
$25 ,20 0 NE
20–24 57.7 (38.7 to 76.7) 1.1 (0.8 to –1.5) 0.714 1.0 (0.7 to 1.4) 0.869
$25 54.2 (51.8 to 56.7) Reference —
*Adjusted for clinic and previous pregnancy.
ARR, adjusted relative risk; NE, non estimable; RR, unadjusted relative risk.
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outcome measurement of HIV sero-positivity could poten-
tially be misclassified because of the use of different
laboratory methods and tests, even though these tests have
a sensitivity and specificity in excess of 98.2% and have been
used extensively in national surveillance programs.13,44,45
Nevertheless it is possible that these tests may yield non-
specific reactions due to causes other than HIV, in low or high
HIV prevalence settings and therefore have the risk of
misclassification. Although we aimed to collect data on
ART use from 2009, we obtained a low response rate which
could be due to HIV-related stigma and discriminations,
which remain pervasive in this community.46–49 We therefore
relied on the district ART data.10,11
To conclude, notwithstanding limitations inherent in
cross-sectional surveys and with behavioral data collection
specifically of women’s recall bias of their partner’s age,
these data demonstrate an unequivocal and unambiguously
high pregnancy rate and HIV prevalence in this rural
community, and highlight partner age as an important risk
factor in HIV acquisition among young women. Given the
8–10 year latency between HIV infection and AIDS related
morbidity and mortality,50 the continued scale-up of ART
services at primary health care clinics could be key to averting
a further AIDS catastrophe in this setting. To what extent
survival of these communities, already with limited economic
and productive capacity, is compromised, is hard to predict.
Inclusion of young women in our quest for new biomedical
and behavioral modalities to reduce HIV risk remains an
urgent imperative.
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